go-v.orgdoi

Denosumab in the treatment of bone metastases

EJ Woodward, JE Brown · Clinical Investigation · 2012

  • DOI 10.4155/cli.12.38
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2012

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2012

Abstract

Metastatic bone disease has a major impact on both the morbidity and mortality of patients. Antiresorptive bisphosphonates have revolutionized treatment and outcomes for patients with bone metastases, but pain and other skeletal complications still occur, adversely affecting quality of life and survival. Recent understanding of the bone microenvironment has highlighted the importance of RANK, its ligand (RANKL) and the decoy receptor OPG in the vicious cycle of bone resorption and destruction. Exploiting this triad led to the development of denosumab, a fully-human monoclonal antibody to RANKL.

The success of this bone-directed agent in early clinical trials and favorable safety and tolerability profile led to the conduct of large multi-center randomized trials in breast, prostate, myeloma and other advanced cancers. In this review, we discuss the development of denosumab, the data that led to its licensing for patients with bone metastases and the future for bone-directed therapies.

Open the resolved locator · 10.4155/cli.12.38

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 02:09 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.12.38
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.